• Specialties

Cardiovascular Disease (Board Certified)
Interventional Cardiology (Board Certified)
Endovascular Medicine (Board Certified)

• What I Love About My Job

“Patients want their physician to listen and address their personal health concerns.”

Great healthcare is about the quality of the interaction between the patient and their physician. It is a trust I take seriously and I promise to give you my utmost attention as well as my expertise. My patients’ well being is my greatest reward.

• Education

Medical School: King Edward Medical College
Residency: The Mayo Clinic
Fellowship: Cedars Sinai Medical Center

• Affiliations

Scripps Memorial Hospital

Sharp Chula Vista Medical Center

Paradise Valley Hospital

Helped establish and directed Scripps Clinic’s first fellowship program in Peripheral Vascular Interventions and trained the first Scripps fellows in peripheral interventions.

• Diplomate, American Board of Vascular Medicine, 2007
• Diplomate, American Board of Endovascular Medicine, 2007
• Diplomate, American Board of Interventional Cardiology, 2002
• Diplomate, American Board of Cardiovascular Diseases, 1997
• Diplomate, American Board of Internal Medicine, 1994
• Member, Royal College of Physicians, MRCP (UK), 1988
• Diploma, Tropical Medicine and Hygiene, DTM&H (UK), 1987

• Safety of day-case endovascular interventions for peripheral arterial disease in a rural, underserved area.
• Co- Investigator STEEPLE Study – XRP 4563/4001
  (Principal Investigator – Brian Jaski, MD)
  An international phase 2 to 3, stratified, randomized, open-label, parallel-group clinical trial to evaluate the safety and efficacy of a single intravenous bolus of enoxaparin versus intravenous unfractionated heparin in patients undergoing non-emergent Percutanous Coronary Intervention at Sharp Memorial Hospital 09/01/2004 through 02/28/2005
• Co-Investigator SPIDER (Principal Investigator: John Gordon, M.D.): SVG Protection in a distal embolic protection randomized trial at Sharp Memorial Hospital – 02/20/2004 through 03/31/2005
• Co-Investigator TRITON-TIMI 38 (Principal Investigator: John Gordon, M.D.) – A comparison of (CS-747) and clopidogrel in acute coronary syndrome subjects who are to undergo percutaenous coronary intervention.
  Sponsored by Eli Lilly and Company. Study began 11/01/2005 at Sharp Memorial Hospital.
• Co-Investigator SPIDER (Principal Investigator: John Gordon, M.D.): SVG Protection in a distal embolic protection randomized trial at Sharp Memorial Hospital – 02/20/2004 through 03/31/2005
• Role of Transesophageal Echocardiography in Endocarditis (In collaboration with the Mayo Clinic, Rochester, MN.)
  Piperacillian / Tazabactam in Treatment of Serious Acute Soft Tissue Infections. Drugs Exp Clin Res 187-90 In 1992.
• Abnormal Myocardial Perfussion Single Photon Emission Computed Tomography and Normal Coronary Arteriogram:
  The Role of Intracoronary Vascular Ultrasound in Providing Diagnostic Confirmation. (American Heart Journal 130/ (1) 182-186 July 1995) Kiat H, Ansari A, Berman D.
• Role of Dobutamine Echocardiography in Assessment of Myocarcdial Viability in 1994.
• High Dose Oral Fluconazole For Oralpharyngeal Candidiasis in AIDS (Journal of Anti-microbial Chemotherapy 1990 Vol. 25 pp 720-721) from 1990 to 1992.
• Coordinator ISIS III Trial (International Study on Infarct Survival) University of Aberdeen, Scotland 1989 – 1990
• Observation on Rheumatic Heart Disease in Pakistan (Pakistan Heart Journal Vol. 22, Issue I Jan – Mar ’89 pp 2-7)

• Challenges in Interventional Cardiology (New Delhi, India, March 2005)
• New Trends in Interventional Cardiology (Hong Kong, April 2004)
• Drug Eluting Stents Impact on Coronary Artery Disease (Punjab Institute of Cardiology, March 2002)
• Assessment of thrombosis using Techoflex coating on a nitinol stent in a rabbit model in 1994.
• Comparison of Johnson & Johnson stent and HARTS device for thrombosis in a porcine model in 1994.